Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2025-04-09

Clinical Trial Update: A Study to Investigate Leramistat in Patients With IPF [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Leramistat for idiopathic pulmonary fibrosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Leramistat

Snippet

Sponsor: Modern Biosciences Ltd | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: WITHDRAWN